Week in Review: China Pharma Signs Cross-Border Deals

China's Tasly Pharma invested $22 million in Pharnext of France and formed a JV to develop new combination drugs that will include TCM products; Shanghai Fosun Pharma contributed $15 million to an early-stage fund developing medical research products from Partners Healthcare System of Boston; Innovative Cellular of Shanghai entered a $14 million deal for greater China rights to four cell therapy products from Boston's Vericel; Medtronic signed an option to acquire the Chocolate® PTA Balloon Catheter from Singapore's QT Vascular for $28 million; Japan's Otsuka Pharma agreed to a $865 million deal for non-US rights (including China) to a late-stage anemia drug from Akebia Therapeutics of Boston; Inner Mongolia Furui Medical Science formed a China JV with Theraclion of France to market Theraclion's HIFU surgery device; and Aslan Pharma of Singapore began its Taiwan IPO, which will raise at least $28 million, with a three-day public auction of 10.4 million shares; More details.... Stock Symbols: (TT: 6497) (SHA: 600535) (Paris: ALPHA) (SHA: 600196; HK: 2196) (NYSE: MDT) (SGX: 510) (NSDQ: VCEL) (Alternext: FR0010120402) (SHZ: 300049) Share this with colleagues: // //